Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
September 19, 2024 14:20 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
September 09, 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
September 04, 2024 09:20 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma, Inc. Announces Reverse Stock Split
July 30, 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
June 17, 2024 08:30 ET
|
Evoke Pharma, Inc.
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA...
Evoke Pharma Reports First Quarter 2024 Financial Results
May 14, 2024 16:15 ET
|
Evoke Pharma, Inc.
114% year-over-year increase in net product sales70% prescriber growth in Q1 2024 compared to Q4 2023Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif.,...
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
March 21, 2024 16:15 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
March 07, 2024 16:10 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an...
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
August 07, 2023 08:30 ET
|
Evoke Pharma, Inc.
Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize...
Evoke Pharma Reports First Quarter 2023 Financial Results
May 15, 2023 16:05 ET
|
Evoke Pharma, Inc.
Net product sales increased by 94% from Q1 2022New cumulative prescribers up by 17% from Q4 2022Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif., May 15, 2023 (GLOBE...